Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 931071, 5 pages
http://dx.doi.org/10.1155/2012/931071
Research Article

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization

1Bone Marrow Transplant Program, Section of Hematology/Oncology, Department of Medicine, Georgia Health Sciences University, Augusta, GA 30912, USA
2Department of Pharmacy, Georgia Health Sciences University, Augusta, GA, USA
3Osborn Hematopoietic Malignancy and Transplant Program, West Virginia University, Morgantown, WV 26506, USA

Received 21 December 2011; Accepted 8 February 2012

Academic Editor: Edward A. Copelan

Copyright © 2012 Farrukh T. Awan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Gertz, “Current status of stem cell mobilization: review,” British Journal of Haematology, vol. 150, no. 6, pp. 647–662, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. H. Cottler-Fox, T. Lapidot, I. Petit et al., “Stem cell mobilization,” Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, pp. 419–437, 2003. View at Google Scholar · View at Scopus
  3. J. F. DiPersio, I. N. Micallef, P. J. Stiff et al., “Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4767–4773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. F. DiPersio, E. A. Stadtmauer, A. Nademanee et al., “Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma,” Blood, vol. 113, no. 23, pp. 5720–5726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Gai, M. Holt, B. Nervi et al., “Kinetics of hematopoietic progenitor cell mobilization with cyclophosphamide or cyclophosphamide plus AMD3100 using a mouse model,” Blood, vol. 106: 5217, 2005. View at Google Scholar
  6. S. M. Devine, R. Vij, M. Rettig et al., “Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction,” Blood, vol. 112, no. 4, pp. 990–998, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Flomenberg, R. L. Comenzo, K. Badel, and G. Calandra, “Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation,” Biology of Blood and Marrow Transplantation, vol. 16, no. 5, pp. 695–700, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Flomenberg, S. M. Devine, J. F. DiPersio et al., “The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone,” Blood, vol. 106, no. 5, pp. 1867–1874, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Milone, S. Leotta, F. Indelicato et al., “G-CSF Alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment,” Bone Marrow Transplantation, vol. 31, no. 9, pp. 747–754, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Hosing, R. M. Saliba, S. Ahlawat et al., “Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma,” American Journal of Hematology, vol. 84, no. 6, pp. 335–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Watanabe, T. Watanabe, H. Suzuya et al., “Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor,” Bone Marrow Transplantation, vol. 37, no. 7, pp. 661–668, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. D'Addio, A. Curti, N. Worel et al., “The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF,” Bone Marrow Transplantation, vol. 46, no. 3, pp. 356–363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Hübel, M. M. Fresen, H. Salwender et al., “Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program,” Bone Marrow Transplantation, vol. 46, no. 8, pp. 1045–1052, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Jantunen, K. Penttilä, M. Pyörälä, E. Mahlamäki, T. Kuittinen, and T. Nousiainen, “Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients,” Bone Marrow Transplantation, vol. 46, no. 2, pp. 308–309, 2011. View at Publisher · View at Google Scholar
  15. E. Jantunen and R. M. Lemoli, “Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept,” Transfusion. In press.
  16. G. Calandra, J. McCarty, J. McGuirk et al., “AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data,” Bone Marrow Transplantation, vol. 41, no. 4, pp. 331–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Dugan, R. T. Maziarz, W. I. Bensinger et al., “Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization,” Bone Marrow Transplantation, vol. 45, no. 1, pp. 39–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Shaughnessy, M. Islas-Ohlmayer, J. Murphy et al., “Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide,” Biology of Blood and Marrow Transplantation, vol. 17, no. 5, pp. 729–736, 2011. View at Publisher · View at Google Scholar · View at Scopus